Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
|Videos|April 18, 2018
Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
Author(s)Douglas T. Fearon, MD
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
Advertisement
In this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
Advertisement
Related to this article
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
A personalized ctDNA assay demonstrated 100% specificity but limited sensitivity for detecting recurrence after liver transplantation in HCC and CCA.
The FDA has approved lirafugratinib for advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement based on the phase 1/2 ReFocus trial.
Beth Erickson, MD, FACR, FASTRO, FABS, discussed pioneering MRI-guided brachytherapy at MCW and her priorities as incoming ASTRO president-elect.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
2
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
5